Clinical trials
Myeloproliferative Neoplasms (MPN) clinical trials
Below are recruiting myeloproliferative neoplasms (mpn) clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07410247Recruiting
Registry for children with MPN blood cancers
This study tracks children and teens with certain rare blood cancers called myeloproliferative neoplasms (MPNs). By collecting information from many patients, doctors hope to better understand these conditions and improve care for young people.
Erlangen, BavariaAges birth–17 years - NCT05025488RecruitingPhase 1
CALR-mutant blood cancer vaccine for adults with high-risk ET or PMF
This Phase 1 study tests a vaccine made from a CALR mutation (a specific genetic change) to help the immune system recognize and fight your blood cancer. It is mainly focused on early safety and to see if the vaccine can trigger an immune response in people with CALR-mutated myeloproliferative neoplasms.
New York, New YorkAges 18 years+ - NCT05835466RecruitingPhase 2
Reparixin for myelofibrosis patients who can’t use JAK inhibitors
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Tampa, FloridaAges 18 years+ - NCT03630991RecruitingPhase 1
Calcium chelator medicine for AML or MDS during chemotherapy
This Phase 1 study tests whether edetate calcium disodium (also called succimer) can be safely given to people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) while they are on chemotherapy. The goal is to learn the safest dose and whether it has signs of helping the blood cancer respond to treatment.
Houston, TexasAges 1 year+ - NCT07204392Recruiting
Genetic study for early-onset or familial MPN
This study explores whether certain inherited gene changes make people more likely to develop myeloproliferative neoplasms (MPNs). It is looking at patients who were diagnosed at a young age or have a family history of blood cancers, to better understand the genetic causes of these conditions.
Pavia, LombardyAges 18 years+ - NCT02760238Recruiting
Myeloproliferative Neoplasms patient registry study
This is a research registry for people who have certain blood cancers called myeloproliferative neoplasms (MPNs). It helps researchers learn about the disease over time and may help future studies find and compare patients.
Toronto, OntarioAges Any age - NCT05842603Recruiting
Lifestyle program to help people with MPN move more
This pilot study tests a lifestyle and movement program for adults with certain myeloproliferative neoplasms (MPNs), aiming to improve well-being through safe exercise habits. You may be considered if you have an MPN and at least one heart-related risk factor.
Boston, MassachusettsAges 18 years+ - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT05326919Recruiting
Study biobank for people newly diagnosed with certain blood cancers
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
BobignyAges Any age - NCT06462664Recruiting
Monocytes and myeloproliferative neoplasms study
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
BrestAges 18 years+ - NCT06715267Recruiting
MPN in youth: studying disease features and complications
This study looks at young people (children, teens, and adults under 30) who have a type of blood cancer called myeloproliferative neoplasm (MPN). It aims to better understand the disease and its complications over time, with the goal of improving care.
BrestAges birth–30 years - NCT05553873Recruiting
Study links inflammation levels to outcomes in MPN patients
This study looks at inflammation-related lab markers in people with “Ph-negative” myeloproliferative neoplasms (like PV, ET, or PMF) to see how they relate to outcomes and response to treatment. It’s observational, meaning it gathers information from medical records without testing a new treatment.
BariAges 18–99 - NCT07419178Recruiting
New scan test for scarring in blood cancers
This study tests a new way to detect scar tissue in the bone marrow using a special scan and blood test. It might help doctors see how your disease is changing without needing a bone marrow biopsy.
Parma, ItalyAges 18 years+ - NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+ - NCT04493164RecruitingPhase 2
CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Houston, TexasAges 18 years+ - NCT05198960RecruitingPhase 3
Blood thinner drugs vs aspirin to prevent clot problems
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
AngersAges 18 years+ - NCT05745285Recruiting
LLS care support program for blood cancer patients
This study looks at whether LLS services and support improve outcomes and the day-to-day experience of care for people with leukemia, lymphoma, myeloma, MDS, or MPN. It’s mainly about matching you to the right support and following your progress for 6 months.
Miami, FloridaAges 18 years+ - NCT06063486RecruitingPhase 2
Curcumin for inflammation and symptoms in blood disorders
This trial tests whether curcumin, a natural compound found in turmeric, can reduce inflammation and improve symptoms like fatigue in people with certain blood disorders that cause low blood counts or overproduction of blood cells. It is for patients with clonal cytopenia of uncertain significance, low-risk myelodysplastic syndrome, or myeloproliferative neoplasms (polycythemia vera, essential thrombocytosis, or myelofibrosis) who have bothersome symptoms.
Los Angeles, CaliforniaAges 18 years+ - NCT06541249RecruitingPhase 2
Adding methotrexate for blood cancers not controlled by current therapy
This trial is testing whether adding a low dose of methotrexate (a medicine often used for arthritis) can help people with certain blood cancers (myelofibrosis, polycythemia vera, or essential thrombocythemia) whose current treatments are not controlling their symptoms or blood counts well enough.
New York, New YorkAges 18 years+ - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80
Hear when a new Myeloproliferative Neoplasms (MPN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloproliferative neoplasms (mpn)?
- Yes. Clin2 currently lists 44 recruiting myeloproliferative neoplasms (mpn) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloproliferative neoplasms (mpn) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloproliferative neoplasms (mpn) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.